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Alleviating the personal and social burden associated with substance use disorders 
requires the implementation of a comprehensive strategy, including outreach, education, 
community interventions, psychiatric treatment, and access to needle exchange 
programs (NEP), where peer support may be available. Given that substantial research 
underscores the potential benefits of peer support in psychiatric interventions, we aimed 
to conduct a national survey to examine key domains of mental health status in people 
who inject drugs (PWID) in New Zealand. PWID were recruited from 24 pharmacies and 
16 dedicated peer-based needle exchanges (PBNEs) across the country. We focused 
on two mental health outcomes: (1) affective dysregulation, across the three emotional 
domains of the Depression Anxiety Stress Scale, due to its role in the maintenance of 
continued drug use, and (2) positive cognition and effective health- and drug-related 
information exchange with the provider, using the Satisfaction with Life Scale and an 
ad  hoc questionnaire, respectively, in view of their association with improved mental 
health outcomes. We hypothesized that access to peer support would be associated 
with mental health benefits for PWIDs. Remarkably, the results of a multistep regression 
analysis revealed that irrespective of sex, age, ethnicity, main drug used, length of drug 
use, and frequency of visits to the NEP, the exclusive or preferential use of PBNEs 
predicted significantly lower depression and anxiety scores, greater satisfaction with 
life, and increased health-related information exchange with the service provider. These 
findings demonstrate for the first time an association between access to peer support 
at PBNEs and positive indices of mental health, lending strong support to the effective 
integration of such peer-delivered NEP services into the network of mental health services 
for PWID worldwide.
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inTrODUcTiOn
It is estimated that approximately 16 million people worldwide inject drugs (1). Sharing of drug 
taking equipment continues to be a major cause of transmission of blood-borne viruses, such as HIV 
and hepatitis C. Such negative association is especially burdensome in countries with no or poor 
roll-out needle exchange programs (NEP) and is accentuated by a lack of awareness and education 
about safe injecting (2). Albeit the services provided vary significantly from country to country, the 
2Hay et al. Peer Support at Needle Exchanges
Frontiers in Psychiatry | www.frontiersin.org January 2017 | Volume 7 | Article 211
implementation of harm reduction strategies, currently defined as 
a comprehensive package aimed at the prevention, treatment, and 
care for people who inject drugs (PWID), is widely recognized as 
a satisfactory evidence-based approach to minimize the health 
risks associated with injecting drugs (3). Key elements of such 
intervention are the provision of safe equipment and materials, 
provision of up-to-date information about safe injecting prac-
tices, and access to health and counseling referrals.
Stimulated by changes of drug policy in the Netherlands that 
shifted the focus from detoxification to harm reduction, an envi-
ronment permissive to self-organization of PWID led to the for-
mation of the first underground exchanges (the “junkiebonden”) 
in the early 1980s. Some years later, fueled by the positive impact 
these organizations were having on the community, funding 
initiatives from the Dutch Ministry of Health led to a spread of 
NEP schemes throughout the country (4). In New Zealand, the 
number of notified cases of AIDS had been growing through the 
1980s (5), and in 1987, the government decriminalized the sale 
of needle and syringes, implementing in 1988 the first nationwide 
NEP in the world (6, 7). Initially conceived as a pharmacy and 
general practitioner service, the New Zealand scheme quickly 
expanded with the addition of drug user groups contracted to 
provide educational support, later constituting charitable trusts 
and independent NEP operating a peer-to-peer system. At 
present, there are some 180 pharmacy outlets and 21 peer-based 
needle exchanges (PBNEs) participating in the New Zealand NEP 
scheme (www.needle.co.nz).
The peer-based strategy, which in New Zealand has evolved 
from the peer user groups of the 1980s, is an organic process 
whereby clients, rather than staff, provide direct service to their 
peers, particularly in the distribution of needles, syringes, and 
associated injection equipment. Building on existing commu-
nity networks, trained peers assist PWID to access exchangers, 
distribute information about safer drug use and safer sex, and 
facilitate referrals to other user-friendly health services. Although 
not exempt of limitations and shortcomings (8), the peer service 
model, in addition to disseminating safer practices and making 
a variety of health services more accessible, emphasizes the 
importance of reconstructing relationships with family, friends, 
and the community at large (9, 10), which may ultimately con-
tribute to promote greater psychological stability and enhance 
the benefits of psychiatric interventions. In the area of mental 
health, there is considerable theoretical and experiential support 
for the notion that peer support may exert a positive influence 
in multiple relevant domains, including empowerment (11), 
symptom distress (12), self-esteem (13), and social integration 
(14). However, no previous studies have investigated the potential 
psychiatric benefits of peer support in the context of NEP on a 
large scale. We conducted a nationwide survey aimed at explor-
ing the psychological well-being of PWID using pharmacies and 
PBNEs across New Zealand.
In the present study, we drew on the well-established triad of 
affect, cognition, and behavior, as key psychological mechanisms 
influencing health outcomes (15). By using this framework, 
we assessed two psychological health outcomes: (i) affect and 
(ii) cognitions and behaviors. First, we examined measures of 
general affect prompted by the close association between positive 
and negative affect states as possible inductors or outcomes 
for sustained drug use (16). Second, we assessed the extent to 
which individuals demonstrated positive cognitions about life 
and felt able to both share personal health-related information 
and access information on safe drug use, as these cognitions and 
behaviors are linked to wellness, enhanced risk perception, and 
self-efficacy (17).
MaTerials anD MeThODs
sample
Peer-based needle exchanges and pharmacies (Levels 1 and 2 out-
lets, see www.needle.co.nz for a complete description of services 
and type) under the NEP scheme received the questionnaires by 
post. Included with the questionnaires there was a prepaid postal 
bag and an instructions sheet for staff. At each pharmacy or peer-
based outlet, there was one main contact person (usually the man-
ager of the pharmacy or NEP) who was briefed personally or over 
the phone and instructed to inform all staff to hand out the survey 
to PWID. PWID were asked to participate in the survey and those 
who expressed willingness were first given an information sheet 
with details of the general purpose of the study. The information 
sheet indicated that the information provided by participants 
would remain anonymous at all times and that through comple-
tion of the survey consent would be obtained to use the data for 
analysis and publication. For this purpose, each NEP was asked to 
allocate a private space within their premises. No interviewer was 
present to prevent bias. The survey was completed by the PWID 
with no time limit. The estimated time to complete it was 30 min 
approximately. To compensate for the time invested in complet-
ing the questionnaire, a NZ $10 supermarket voucher was given 
to the participants. Surveys were collected from 315 respondents 
(170 males, 141 females, with 4 who did not disclose their sex), 
aged from 19 to 66  years (mean age =  42.40, SD =  9.2), from 
regions throughout the north (Auckland, Palmerston, Midlands, 
Wellington, Northland, and Napier) and south (Christchurch/
Canterbury, Dunedin/Southland, and Nelson/Malborough) 
islands of New Zealand, including 24 pharmacies (16 in the 
north island and 8 in the south island) and 16 PBNEs (11 in the 
north island and 5 in the south island). The study was approved 
by the Human Ethics Committee of the University of Canterbury 
and by the New Zealand NEP, the Pharmaceutical Society, and 
the Pharmacy Guild of New Zealand. The authors assert that all 
procedures contributing to this work comply with the ethical 
standards of the relevant national and institutional committees 
on human experimentation and with the Helsinki Declaration of 
1975, as revised in 2008. Table 1 provides a summary of other 
demographic and drug use data relating to ethnicity, type and 
main drug used, length of drug use, preferred use of NEP, and 
frequency of visits to the NEP.
assessment of affective state
To assess the psychological status of the PWID in the affective 
domain, the Depression Anxiety Stress Scale 21 (DASS-21), a 
short form of Lovibond and Lovibond’s 42-item self-report, was 
utilized (18). DASS-21 comprises three dimensions of seven items 
each: depression, anxiety, and stress. The scale aims to capture an 
Demographic/ 
drug use variable
Frequency
Frequency of visits to NEP 1–2 times a month (n = 118)
3–4 times a month (n = 96)
5–6 times a month (n = 38)
7+ times a month (n = 58)
Missing (n = 5)
TaBle 1 | Demographic and drug use data relating to ethnicity, 
occupation, type and main drug used, length of drug use, preferred use 
of neP, and frequency of visits to the neP.
Demographic/ 
drug use variable
Frequency
Ethnicity New Zealand European (n = 233)
Maori (n = 65)
Pasifika (n = 6)
Other (n = 5)
Asian (n = 3)
Missing (n = 3)
Occupation Unemployed/benefits (n = 149)
General laborer and service (n = 47)
Homemaker (n = 36)
Semi-professional/professional (n = 29)
Sales and marketing (n = 19)
Semi-skilled laborer or service (n = 12),  
student/volunteer, pension (n = 7)
Arts (n = 3)
Self-employed (n = 2)
Missing (n = 11)
Main drug type Opiates (n = 188)
Stimulants (n = 91)
Other (n = 20)
Missing (n = 16)
Type of drugs taken in the 
last month
Methadone (n = 183)
Morphine (n = 166)
Amphetamines (n = 126)
Ritalin (n = 103)
Benzodiazepines (n = 32)
Homebake (n = 26)
Other (n = 14)
Cocaine (n = 8)
Opium (n = 7)
Anabolic (n = 4)
Ecstasy (n = 3)
Cyclizine (n = 2)
Benzylpiperazine (n = 2)
Tramadol (n = 1)
Methylone (n = 1)
Palfium (n = 1)
Length of use More then 10+ years (n = 218)
8–9 years (n = 18)
6–7 years (n = 18)
4–5 years (n = 21)
2–3 years (n = 24)
0–1 year (n = 10)
Missing (n = 6)
Preferential use of the  
peer-based needle exchange
I always use peer-based needle exchange 
(n = 154)
Not always, but nearly every time I use the peer-
based needle exchange (n = 24)
I tend to use the peer-based needle exchange 
more often (n = 10)
I use the peer-based needle exchange and the 
pharmacies about the same number of times 
(n = 20)
I tend to use the pharmacies more often  
(n = 13)
Not always, but nearly every time I use the 
pharmacies (n = 14)
I always use the pharmacies (n = 76)
Missing (n = 4) 
(Continued )
TaBle 1 | continued
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individual’s distress by evaluating these three common negative 
emotional states. Each question is answered on a 4-point Likert 
scale: 0 (never), 1 (sometimes), 2 (often), and 3 (almost always). 
Evidence has shown the reliability and validity (i.e., internal 
consistency and test-retest) of the scale in both clinical and non-
clinical settings (18–20).
assessment of Well-Being
The Diener Satisfaction with Life Scale (SWLS) was used as a 
reliable indicator of subjective well-being (21). This scale consists 
of five items designed to measure global cognitive judgments of 
one’s life satisfaction. The participant is required to answer each 
question on a 7-point Likert scale: 1 (strongly disagree) to 7 
(strongly agree). Past research supports the reliability and validity 
of this scale (22).
assessment of health-related information 
exchange
To examine the self-perceived ability of PWID to share experi-
ential information in relation to their drug use, including health 
information, and to access information on drug use and safe 
practices, a 5-point Likert questionnaire consisting of eight ad hoc 
questions was devised. This health-related information exchange 
questionnaire (IEQ) included questions aimed to measure the 
degree to which PWID were willing to share personal experi-
ences at the NEP, felt they had an adequate knowledge about safe 
practices, felt comfortable about asking questions regarding drug 
use and health referral services, and perceived the information 
available at the NEP as being useful and effective.
resUlTs
Missing Data
Across the 10 variables for which data were collected [of which 
three of the perceived variables (negative affect, satisfaction with 
life and information exchange) comprised 32 items], 90 cases 
were removed from the analysis due to missing data, leaving a 
cohort size of n = 225 (124 males, 101 females, mean age = 42.37, 
SD = 9.12). A series of independent group t tests and chi-square test 
[we used SPSS for Windows 22 (IBM Corp, 2013) for all statistical 
tests] were computed for those variables for whom individuals 
were removed due to having some missing data [ranging from 
n = 67 to 86 (as data remained for some of these individuals for 
other variables in the analysis)] and those individuals included in 
the analysis (n = 225). Table 2 shows that no statistical significant 
differences occurred for mean scores between both groups for the 
established variables: DASS, SWLS, age, length of use, frequency 
TaBle 3 | clinical caseness of depression, anxiety, and stress scores 
for the current sample as determined by severity rating provided in the 
Depression anxiety stress scale manual.
severity Depression anxiety stress
Frequency % Frequency % Frequency %
Normal 71 31.6 70 31.1 98 43.6
Mild 32 14.2 20 8.9 38 16.9
Moderate 50 22.2 46 20.4 31 13.8
Severe 34 15.1 24 10.7 39 17.3
Extremely 
severe
38 16.9 65 28.9 19 8.4
TaBle 2 | Mean scores for health-related information exchange, Depression anxiety stress scale (Dass) subscales, satisfaction with life, preferred use 
of needle exchange programs (neP), frequency of visits, and age by people who inject drugs included and excluded from the analysis.
Variable excluded (n) Mean sD included (n) Mean sD t p
Health-related information exchange 75 31.52 6.21 225 31.96 6.13 0.58 0.592
Depression (DASS) 74 16.54 12.74 225 15.68 10.50 0.45 0.652
Anxiety (DASS) 67 14.15 12.26 225 13.72 9.88 0.30 0.766
Stress (DASS) 71 17.80 12.54 225 17.13 10.44 0.45 0.652
Satisfaction with life 85 17.87 8.24 225 16.80 7.25 1.12 0.265
Use of NEP 86 3.62 2.65 225 3.03 2.52 1.81 0.072
Length of use 84 5.00 1.60 225 5.20 1.46 −1.07 0.286
Frequency of visits 85 2.00 1.04 225 2.16 1.14 −1.13 0.260
Age 74 42.50 9.70 225 42.39 9.12 0.11 0.916
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of visits to the NEP, and preferred use of NEP. Furthermore, no 
significant association was found between inclusion and exclu-
sion due to missing data for sex (χ2 = 0.07, p = 0.797), ethnicity 
(χ2 = 0.09, p = 0.765), and main drug of use (χ2 = 3.03, p = 0.082).
clinical caseness
To demonstrate the clinical casesness of affective state among 
the respondents, the DASS provides severity ratings for each of 
the subscales of depression, anxiety, and stress. Table 3 shows a 
breakdown of the scores by each of the severity rating provided 
by the DASS manual scoring.
Factor analysis
With the measures we collected, we identified three possible 
domains: emotional evaluations of affect (comprising depres-
sion, anxiety, and stress of the DASS), cognitive evaluations of 
affect (comprising SWLS scores), and health-related information 
exchange (comprising the IEQ scores). To explore these as three 
separate outcome domains, we performed an exploratory factor 
analysis to explore the underlying structure of the items from 
the DASS, SWLS, and IEQ. The number of participants (225) to 
variables (34) ratio (6.6:1) exceeded the recommended minimum 
ratio needed for EFA of 5 to 1 (with a minimum number of par-
ticipants of 150) (23, 24). All items were subjected to maximum 
likelihood analysis (Kaiser–Meyer–Olkin measure of sampling 
adequacy = 0.92; Bartlett’s test of sphericity, (2 = 4,749.93, df = 561, 
p <  0.001). To determine the number of factors to extract, we 
performed a parallel analysis of Monte Carlo simulations (25) 
that allowed us to determine the number of factors by compar-
ing the eigenvalues of a higher value with those that might be 
expected from purely random data. The fourth eigenvalue (11.40, 
4.79, 2.62, and 1.26) failed to exceed the fourth mean eigenvalue 
(1.82, 1.71, 1.63, and 1.56) calculated from 1,000 generated data 
sets with 225 cases and 34 variables, suggesting that a 3-factor 
solution was appropriate. Therefore, a three-factor solution was 
explored using a promax rotation, as we expected the factors to 
be correlated, with delta set to 0. The results of this analysis are 
presented in Table 4.
Meaningful loadings were assessed using the criteria of 0.32 
(“poor”), 0.45 (“fair”), 0.55 (“good”), 0.63 (“very good”), and 0.71 
(“excellent”) (26). From this solution, all the items from the DASS 
loaded on the first factor, with one item loading with a value of 
0.33 and the rest of loadings ranging from 0.48 to 0.86. All the 
IEQ items loaded on the second factor with one item loading 
with a value of 0.34, and the rest of the loading values ranging 
from 0.52 to 0.89. Finally, all the SWLS items loaded on the third 
factor, with loading values ranging from 0.54 to 0.91. Moreover, 
the correlations between the factors ranged from −0.10 to −0.50, 
suggesting the factors had no more than 25% of shared variance. 
Therefore, the current findings suggest that the current items used 
fall under three different general domain: emotional evaluations 
of affect (in which higher scores represent higher levels of nega-
tive emotional affect), cognitive evaluations of affect (in which 
higher scores represent higher levels of positive cognitive affect), 
and self-perceived ability to share and access relevant health 
information (in which higher scores represent higher levels of 
health-related information exchange).
However, the finding that the items of the DASS load on one 
factor in this context questions whether the DASS scores is best 
represented, at least in this sample, by one overall score, or is 
best considered in terms of three factors, given theoretical and 
empirical evidence that the DASS commonly forms three factors 
of depression, anxiety, and stress (18). Therefore, we subjected 
just the items of the DASS scale to a confirmatory factor analysis 
(CFA). A key focus of CFA is to demonstrate the incremental 
value of proposed models (27). We compared the goodness of 
fit, a unidimensional model, representing an underlying latent 
factor structure of negative affect with a three-factor model com-
prising depression, anxiety, and stress. To assess the goodness 
of fit of the data, we looked at the five statistics recommended 
by Hu and Bentner (28) and Kline (29): the relative χ2 (CMIN/
DF), the comparative fit index (CFI), the non-normed fit index 
(NNFI), the root mean square error of approximation (RMSEA), 
and the standardized root mean square residual (SRMR). The 
following are the criteria to assess whether the model fit was 
TaBle 4 | exploratory factor analysis of the Dass, satisfaction with life, and health-related information exchange items.
items Factor
1 2 3
I found it hard to wind down 0.577 –0.038 0.062
I was aware of dryness of my mouth 0.326 –0.064 0.118
I couldn’t seem to experience any positive feeling at all 0.478 –0.042 –0.096
I experienced breathing difficulty (e.g., excessively rapid breathing, breathlessness in the absence of physical  
exertion)
0.516 –0.077 0.069
I found it difficult to work up the initiative to do things 0.512 –0.097 –0.094
I tended to overreact to situations 0.729 0.022 –0.006
I experienced trembling (e.g., in the hands) 0.612 –0.032 0.097
I felt that I was using a lot of nervous energy 0.824 0.020 0.079
I was worried about situations in which I might panic and make a fool of myself 0.856 0.050 0.198
I felt that I had nothing to look forward to 0.632 0.001 –0.202
I found myself getting agitated 0.773 –0.022 0.001
I found it difficult to relax 0.755 0.048 –0.022
I felt down-hearted and blue 0.659 –0.074 –0.171
I was intolerant of anything that kept me from getting on with what I was doing 0.717 –0.012 0.042
I felt I was close to panic 0.813 0.021 0.061
I was unable to become enthusiastic about anything 0.672 –0.013 –0.141
I felt I wasn’t worth much as a person 0.652 0.034 –0.244
I felt that I was rather touchy 0.727 0.072 –0.047
I was aware of the action of my heart in the absence of physical exertion (e.g., sense of heart rate increase,  
heart missing a beat)
0.734 –0.030 0.171
I felt scared without any good reason 0.825 0.023 0.072
I felt that life was meaningless 0.644 0.015 –0.237
In most ways my life is close to my ideal 0.048 0.041 0.819
The conditions of my life are excellent 0.131 –0.027 0.909
I am satisfied with my life –0.043 –0.042 0.797
So far I have gotten the important things I want in life –0.044 –0.051 0.654
If I could live my life over, I would change almost nothing 0.090 0.020 0.542
Do you feel your needle exchange provides an environment where you feel safe? –0.032 0.704 –0.045
Do you feel you know enough regarding injecting safely? –0.140 0.559 –0.101
Do you feel comfortable to ask your needle exchange questions on drug use? –0.042 0.734 –0.036
Do you share personal experiences regarding your drug use with the needle exchange? 0.003 0.522 –0.024
Does the needle exchange provide information on safe drug use? 0.074 0.878 0.107
Do you feel well informed on safe drug use? –0.061 0.815 0.019
Do you feel your needle exchange is willing to answer questions you may have or are willing to refer you  
to other support services?
0.071 0.892 0.035
Does the needle exchange offer information regarding the accessibility of user-friendly disposal of used needles? –0.031 0.737 –0.014
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“acceptable”: (i) CMIN/DF should be less than three to be 
acceptable, (ii)  the CFI, GFI, and NNFI should exceed 0.90 to 
be acceptable, (iii)  the RMSEA should not exceed 0.08 and be 
below 0.06 to be a “good” fit, and (iv) the SRMR values less than 
0.08 are “acceptable” and those less than 0.05 are “good” (28, 29). 
Improvement on the value of the model was assessed by changes 
in CFI (ΔCFI) being > 0.01 (30).
Comparing the two models, the three-factor model (CMIN/
DF = 2.02, CFI = 0.93, GFI = 0.87, NNFI = 0.92, RMSEA = 0.068, 
SRMR = 0.046) shows acceptable and improved (as indicated by 
ΔCFI being > 0.01) goodness-of-fit statistics over the one-factor 
model (CMIN/DF = 2.98, CFI = 0.87, GFI = 0.78, NNFI = 0.85, 
RMSEA = 0.094, SRMR = 0.059). Therefore, we computed the 
following scale scores to represent three domains, in terms of 
overall scores for SWLS (α = 0.85) to assess cognitive evaluation 
of affect, overall scores for IEQ to assess information sharing 
(α  =  0.87), and the three DASS subscale scores for depression 
(α =  0.90), anxiety (α =  0.84), and stress (α =  0.90) to assess 
emotional evaluations of affect.
Multiple regression
We ran 5 three-step multiple regressions, with overall SWLS 
and IEQ scores and DASS subscales scores used in the series as 
dependent variables, with sex, age, and ethnicity (recoded for 
NZ European [1] versus non-NZ European [2]) as the predictor 
variables in step 1; then main drug used (recoded as opiate [1] 
versus stimulant [2]), length of use, and frequency of visits to the 
NEP as predictor variables in step 2; and, finally, we incorporated 
preferred use of NEP as a predictor variable in step 3. An a priori 
sample size calculator for a multiple regression study, given a 
desired probability level of p <  0.05, the number of predictors 
in the model being 7, the anticipated effect size being medium 
( f 2 = 0.15), and the desired statistical power level of .8, calculated 
the minimum required sample size as n = 103, suggesting that 
our current sample size of n = 227 used for this analysis exceeded 
these criteria. The variance inflation factors (VIFs) and tolerance 
factors for each of the single predictor variables were no larger 
than 1.20 and no smaller than 0.83, respectively. Therefore, they 
did not contravene the threshold values for VIF of at least 5 and 
TaBle 5 | Multiple regression analysis with, Depression anxiety stress scale subscales, satisfaction with life and health-related information exchange 
scores used as a dependent variable, with sex, age, and ethnicity as the predictor variables in step 1; then main drug used, length of use, and frequency 
of visits to neP as predictor variables in step 2; and, finally, preferred use of neP as a predictor variable in step 3.
Depression anxiety stress
B β t p B β t p B β t p
step 1
Sex –0.01 –0.01 –0.01 0.991 0.39 0.04 0.57 0.568 –0.48 –0.05 –0.68 0.499
Age –0.03 –0.05 –0.77 0.442 –0.01 –0.03 –0.38 0.706 –0.06 –0.11 –1.58 0.115
Ethnicity 0.18 0.03 0.37 0.712 0.38 0.06 0.82 0.415 0.73 0.10 1.51 0.132
step 2
Main drug –0.01 –0.01 –0.01 0.991 0.59 0.06 0.77 0.441 –0.06 –0.01 –0.08 0.940
Length of drug use –0.03 –0.05 –0.77 0.442 0.04 0.01 0.14 0.889 –0.06 –0.02 –0.22 0.823
Frequency of visit to NEP 0.18 0.03 0.37 0.712 –0.12 –0.03 –0.41 0.683 0.16 0.04 0.53 0.599
step 3
Preference for use of NEP 0.31 0.15 2.22 0.027 0.32 0.16 2.45 0.015 0.25 0.12 1.79 0.075
satisfaction with life health-related information exchange
B β t p B β t p
step 1
Sex 0.06 0.03 0.43 0.669 0.10 0.05 0.77 0.443
Age 0.01 0.11 1.64 0.103 0.01 0.03 0.45 0.657
Ethnicity 0.09 0.07 0.99 0.325 0.10 0.08 1.15 0.250
step 2
Main drug –0.10 –0.05 –0.72 0.474 –0.25 –0.12 –1.67 0.096
Length of drug use 0.02 0.03 0.45 0.654 –0.08 –0.12 –1.70 0.091
Frequency of visit to NEP –0.03 –0.04 –0.52 0.606 0.01 0.01 0.22 0.830
step 3
Preference for use of NEP –0.06 –0.15 –2.25 0.025 –0.22 –0.57 –10.44 0.001
B = unstandardized beta coefficient; β = standardized beta coefficient; t = t value; p = probability; NEP = needle exchange point (lower scores represent preferences for peer-based 
exchanges).
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tolerance statistics of less than 0.2 that are used to suggest col-
linearity between independent variables (30).
For each regression (see Table  5) in step 1 (depression, 
F[3,221] = 0.25, r = 0.06, r2 = 0.01, adj r2 = 0.01, p = 0.861; anxiety, 
F[3,221] = 0.42, r = 0.08, r2 = 0.01, adj r2 = 0.01, p = 0.741; stress, 
F[3,221] = 1.66, r = 0.15, r2 = 0.02, adj r2 = 0.01, p = 0.175; satis-
faction with life, F[3,221] = 1.22, r = 0.13, r2 = 0.02, adj r2 = 0.01, 
p = 0.305; health-related information exchange, F [3,221] = 0.68, 
r = 0.10, r2 = 0.01, adj r2 = 0.01, p = 0.818) and step 2 (depres-
sion, ΔR2 = 0.01, p = 0.852; anxiety, ΔR2 = 0.01, p = 0.857, stress, 
ΔR2 = 0.01, p = 0.958; satisfaction with life, ΔR2 = 0.01, p = 0.795; 
health-related information exchange, ΔR2 = 0.02, p = 0.174), the 
predictor variables failed demonstrate statistical significance in 
predicting each dimension. In step 3, the inclusion of the prefer-
ence site for the NEP led to a statistically significant change in 
R2 for depression (ΔR2 = 0.02, p = 0.027), anxiety (ΔR2 = 0.03, 
p  =  0.015), satisfaction with life (ΔR2  =  0.02, p  =  0.025), and 
health-related information exchange (ΔR2  =  0.32, p  <  0.001), 
but not stress, although the effect was marginally significant 
(ΔR2 = 0.02, p = 0.075). Data points relating to preferred use of 
NEP and each of the dependent variables are shown in Figure 1.
DiscUssiOn
Although community development programs providing access 
to injecting equipment exist in other countries, including 
European countries, Australia, and USA, there is a considerable 
resistance from governments to support integrated NEP of the 
kind currently implemented in New Zealand (31, 32), with some 
NEP in Europe having been recently dismantled due to political 
opposition (33). In many countries, there remains considerable 
counterproductive, not evidence based, sociopolitical debate 
over the ethical and financial implications of harm reduction 
strategies, despite its proven cost effectiveness (3, 34). Such 
debate fails to address not only the consequences for public 
health in terms of transmission of blood-borne viruses but 
also the psychological and social needs of vulnerable and 
marginalized populations. NEP activities are enabled in New 
Zealand by the Ministry of Health through dedicated (peer 
based) exchanges, mobile units, and participating pharmacy 
outlets. Pharmacies operate at different levels depending on the 
type of injecting equipment provided and distribute educational 
materials to PWID on safe injecting. Dedicated exchanges 
and associated mobile units are run and staffed largely by 
paid workers who have had life experiences as injecting drug 
users themselves and therefore understand the lifestyle and 
challenges PWID face. Albeit training is sparse, such workers 
are well placed to offer advice on safe injecting and available 
referral health services as appropriate. The emphasis of these 
PBNEs is not only on harm reduction but also on a model 
of intentional psychosocial support and outreach, where the 
peers employed in the support role are considered to be further 
FigUre 1 | exclusive of preferential use of peer-based needle exchanges predicts lower levels of depression and anxiety, heightened satisfaction 
with life, and increased health- and drug-relevant information exchange. Box plots show the different levels of the predictor variable, measured with a 
7-point Likert scale, and the scores obtained in the different domains of the Depression Anxiety Stress Scale (i.e., depression, anxiety, and stress), the satisfaction 
with life (SWLS) and the IEQ. The 7-point Likert scale included the following options for the use of peer-based needle exchanges or pharmacies: (1) I always use 
peer-based needle exchange, (2) not always, but nearly every time I use the peer-based needle exchange, (3) I tend to use the peer-based needle exchange more 
often, (4) I use the peer-based needle exchange and the pharmacies about the same number of times, (5) I tend to use the pharmacies more often, (6) not always, 
but nearly every time I use the pharmacies, and (7) I always use the pharmacies. The p values indicate the statistical significance of the correlations between 
preferential use of needle exchanges with measures of depression, anxiety, stress, SWLS, and information exchange questionnaire (IEQ).
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along in their recovery journey. Therefore, they are capable and 
willing to provide leadership, advice, shared life experiences, 
and emotional support to those who enter their services (35, 
36). Sharing credible positive experiences, practical strategies, 
and coping mechanisms has long been regarded as a form of 
support that people with experience in dealing successfully 
with personal mental health problems can offer others facing 
similar challenges (12, 37). Albeit the harm reduction strategy 
implemented by way of NEP is widely recognized to minimize 
the health risks associated with injecting drugs (1), scientific 
evidence that peer support can be of psychological benefit for 
PWID in this specific context is lacking.
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The current study was the first to examine on large-scale key 
aspects linked to mental health status and welfare of PWID using 
peer-based and non-peer-based NEP schemes. Participants were 
recruited from 24 pharmacies and 16 PBNEs across the country of 
New Zealand. We focused on three aspects of well-being, includ-
ing emotional evaluations of negative emotional symptomatol-
ogy (specifically depression, anxiety and stress) (38), cognitive 
evaluations of affect (satisfaction with life), and health-related 
information exchange, as both predictors and outcomes that 
might be linked to improved mental health status and recovery in 
PWID (16). First, the results indicated that the sample of PWID 
comprised a large number of subjects with psychiatric vulner-
ability, as revealed by the severity rating of the DASS (Table 3). 
Second, the findings clearly showed that the preference for 
PBNEs over pharmacy-based services (exchanges) shared unique 
variance with lower depression, lower anxiety, greater satisfaction 
with life, and increased health-related information exchange, 
while controlling for sex, age, ethnicity, main drug used, length 
of drug use, and frequency of visits to the NEP. In terms of the 
salience of these findings, considering the size of unstandardized 
and standardized beta coefficient, that effect was larger for the 
health-related information exchange, with comparatively smaller 
associations for depression, anxiety, and satisfaction with life. 
Notwithstanding, these data show for the first time that the use 
of PBNEs, in comparison with other similar services, is associated 
with positive mental health outcomes.
Where peers are employed as providers of services and sup-
port within traditional or specialized health agencies, peer sup-
port is generally framed within a model of wellness focused on 
effective functioning and recovery rather than the illness and its 
specific symptoms (8). A core feature defining the effectiveness 
of this model is the ability of the peer to engage with clients on 
the same level through increased empathy and deeper under-
standing of their challenges (39). Previous evidence suggests 
that such community-oriented, peer-delivered interactions 
have the potential to engage hard to reach or marginalized 
groups and positively impact on multiple layers of risk and 
behavioral change and particularly on people who regularly use 
drugs (40–42). Peer support has been consistently linked in the 
mental health literature with enhanced acceptance, self-esteem, 
self-efficacy, quality of life, community inclusion, empower-
ment, and willingness to work toward recovery through 
exposure to role modeling and alternative, more functional, 
worldviews (8, 12, 13, 43). The current study was correlational 
in nature and therefore did not allow us to identify the specific 
mechanisms mediating the positive effects of peer services on 
the well-being and affective state of PWID. Notwithstanding, 
the findings for positive mental health outcomes and effective 
health-related information exchange variables revealed an asso-
ciation of the peer support service with positive enhancement 
processes, which may occur via the self or social factors (11, 14). 
Given the nature of the data and the fact that observations were 
collected concurrently, threefold interactions may have given 
rise to such enhancement processes. First, both higher levels 
of effective health-related information exchange and reduced 
affective dysregulation could lead to a preference for PBNEs 
via heightened perceived well-being and self-efficacy, through 
a process akin to self-empowerment (11). Second, a preference 
for PBNEs might reflect elevated levels of social activation (14), 
which in turn could promote greater levels of positive mental 
health and more fluid health-related information exchange 
with the service provider. The third possibility is that the two 
processes combine together, be it within individuals, or across 
the sample.
In terms of recommendations for public and mental health 
policies, the current findings have far-reaching implications for 
the development of effective programs of harm reduction and 
especially for the psychological support and, in cases of psychi-
atric co-morbidity, rehabilitation of PWID. We showed here that 
patent psychological benefits were associated with access to peer 
support at PBNEs in the areas of well-being, affective regulation, 
and effective communication with the service providers. Such 
benefits are likely to impact positively at multiple levels, both 
psychological and social, and could go a long way in facilitating 
remission from continued drug use, recovery, and strengthening 
of social networks within the community. Taken together, these 
findings highlight the need to standardize peer support roles 
in terms of their values, skills, knowledge base, and remit and 
for further integration of such peer-supported programs within 
national policies regulating NEP and health care for PWID 
worldwide.
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